September 2021

Developing modern strategies to predict and accurately monitor treatment response remains an important piece of the clinical management puzzle.

In the phase 3 KEYNOTE-522 trial, pembrolizumab with chemotherapy challenged the standard of care for high-risk, early-stage triple-negative breast cancer with event-free survival improvement.

In an interview prior to the NY Symposium, Perez-Soler, reviewed several areas of development in the lung cancer field that will be addressed during this year’s meeting.

Encouraging results have been reported from the phase 2 Guidance-01 clinical trial.

According to Tycel Jovelle Phillips, MD, the study of venetoclax in combination with the R2 regimen will be expanded to include 50 patients with mantle cell lymphoma without a TP53 mutation.

According to Eliza A. Hawkes, MD, the phase 2 1st FLOR trial showed the positive efficacy of frontline nivolumab in combination with rituximab.

Treatment with larotrectinib in patients with various subtypes of salivary gland tumors led to a high rate early and durable responses.

Responses achieved with immunotherapy preoperatively with could lead to lasting benefit in patients with HOV-associated head and neck squamous cell carcinoma.

A phenomenon known as the “obesity paradox,” has been reported in prostate cancer as well as other genitourinary malignancies.

The emergence of early-phase immune-oncology agents and their respective novel mechanisms of action in head and neck squamous cell carcinoma suggests a new standard of care in the metastatic first-line setting within the next 2 years.

Results from the phase 4 MITO-BCG study show safety of sequential mitomycin with BCG for the treatment of high-risk muscle invasive bladder cancer.

A study has confirmed that androgen receptor inhibition did not complicate robotic prostatectomy surgical outcomes in patients with prostate cancer.

A safety analysis from the phase 3 ARAMIS trial showed that tolerability with darolutamide was comparable with that of placebo in patients with nonmetastatic castration-resistant prostate cancer.

Results shared in a webinar during the 2021 European Association of Urology Congress show the potential of adjuvant pembrolizumab for the treatment of renal cell carcinoma.

After success in malignant melanoma and non–small cell lung cancer, adjuvant treatments are demonstrating improvements in disease-free survival in other cancers, including renal cell carcinoma, esophageal/gastroesophageal cancer, and breast cancer.

During the past 4 decades, glioblastoma has remained a cancer with one of the worst prognoses and is among the most debilitating.

The field is ripe for preventing the undesirable long-term effects of cancer treatment or reducing them altogether through de-intensification, according to Robert L. Ferris, MD, PhD.